Graduation Year
2022
Document Type
Thesis
Degree
M.S.
Degree Name
Master of Science (M.S.)
Degree Granting Department
Public Health
Major Professor
Chaunhai Cao, Ph.D.
Committee Member
Umesh Jinwal, Ph.D.
Committee Member
Wanling Xuan, Ph.D.
Committee Member
Qingyu Zhou, Ph.D.
Keywords
tauopathies, diagnosis, aging, prion-like
Abstract
Parkinson’s Disease is the second most common neurodegenerative disease after Alzheimer’s Disease, and the most common motor disorder. In fact, nearly a third of those with AD have PD. A major hallmark of PD is the appearance of Lewy Bodies, proteinaceous cytoplasm inclusions, that build up and spread throughout the CNS in a prion like fashion. The major component of these Lewy Bodies is a protein called alpha-synuclein. Alpha-syn is a 14kDa protein made of 140 amino acids and found in the presynaptic ends of CNS neurons, acting as a chaperone and regulator. The protein is also found in the rest of the body besides the liver, most importantly in the blood. It has been shown in various studies that targeting alpha-syn can slow down or mitigate the effects of PD. It has also been shown that alpha-syn levels in the blood significantly increase in PD patients compared to non-PD patients. This makes alpha-syn a good biomarker for both diagnosis and potential treatment. However, being able to quickly identify alpha-syn is paramount for quick and efficient diagnosis. In this experiment, I use antibodies, 1H5 and 2A4, to quickly identify relative amounts of alpha-syn in human PD blood plasma. I also used the DOT Blot apparatus as a quick throughput method of antibody staining. The results showed that these monoclonal antibodies combined with using a DOT Blot technique could be used for clinical diagnosis or treatment with proper treatment.
Scholar Commons Citation
Chase, Max, "Alpha Synuclein: A therapeutic target and biomarker for Parkinson’s Disease" (2022). USF Tampa Graduate Theses and Dissertations.
https://digitalcommons.usf.edu/etd/9317